<DOC>
	<DOCNO>NCT00219752</DOCNO>
	<brief_summary>The aim phase II trial ass tolerability effectiveness imatinib patient chronic myelogenous leukemia chronic phase age 70 , diagnosis cml perform within 1 year . Quality life carefully assess .</brief_summary>
	<brief_title>Safety Efficacy Imatinib Chronic Myelogenous Patients Older Than 70 Years</brief_title>
	<detailed_description>Patients receive Imatinib dose 400mg daily . Tolerability quality life assess Secondary objective : evaluate survival without progression , survival without event , overall survival , hematologic , cytogenetic molecular response various check point . Duration responses failure respond evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>CML Ph+ ( assess cytogenetic FISH ) Chronic phase le 5 % bone marrow blast Diagnosis within 12 month Age ≥ 70 year inclusion PS grade 0 2 ( ECOG ) Mini mental status 25 Hydroxyurea optional Imatinib Adequate end organ function , define follow : total bilirubin &lt; 1.5x uln , sgpt &lt; 3x uln , creatinine &lt; 1.5x uln . patient sign inform consent indicate aware investigational nature study keep policy hospital Mini mental status ≤ 25 patient able adequately take study drug Age le 70 accelerated blastic phase previous therapy imatinib interferon HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>CML - ederly patient - Imatinib mesylate</keyword>
</DOC>